Journal article
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study
Journal of clinical oncology, Vol.31(5), pp.558-564
02/10/2013
DOI: 10.1200/JCO.2012.43.7954
PMCID: PMC3565181
PMID: 23295799
Abstract
Randomized data suggest that single-fraction or short-course palliative radiation therapy (RT) is sufficient in the majority of patients with metastatic cancer. We investigated population-based patterns in the use of palliative RT among patients with metastatic non-small-cell lung cancer (NSCLC).
From patients diagnosed with lung cancer from 2003 to 2005 at a participating geographic or organizational site and who consented to the Cancer Care Outcomes Research and Surveillance Consortium study, we identified patients with metastatic NSCLC who had complete medical records abstractions. Patient characteristics and clinical factors associated with receipt of palliative RT and RT intensity (total dose and number of treatments) were evaluated with multivariable regression.
Of 1,574 patients with metastatic NSCLC, 780 (50%) received at least one course of RT, and 21% and 12% received RT to the chest and bone, respectively. Use of palliative RT was associated with younger age at diagnosis and receipt of chemotherapy and surgery to metastatic sites. Among patients receiving palliative bone RT, only 6% received single-fraction treatment. Among patients receiving palliative chest RT, 42% received more than 20 fractions. Patients treated in integrated networks were more likely to receive lower doses and fewer fractions to the bone and chest.
When palliative RT is used in patients with metastatic NSCLC, a substantial proportion of patients receive a greater number of treatments and higher doses than supported by current evidence, suggesting an opportunity to improve care delivery.
Details
- Title: Subtitle
- Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study
- Creators
- Aileen B Chen - Dana-Farber Cancer Institute, 450 Brookline Ave, D1111, Boston, MA 02215, USA. achen7@partners.orgAngel CroninJane C WeeksElizabeth A ChrischillesJennifer MalinJames A HaymanDeborah Schrag
- Resource Type
- Journal article
- Publication Details
- Journal of clinical oncology, Vol.31(5), pp.558-564
- Publisher
- United States
- DOI
- 10.1200/JCO.2012.43.7954
- PMID
- 23295799
- PMCID
- PMC3565181
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- U01 CA093344 / NCI NIH HHS U01 CA093326 / NCI NIH HHS U01 CA093324 / NCI NIH HHS U01 CA093339 / NCI NIH HHS U01 CA093332 / NCI NIH HHS U01 CA093348 / NCI NIH HHS K05 CA166208 / NCI NIH HHS U01 CA093329 / NCI NIH HHS P30 CA086862 / NCI NIH HHS
- Language
- English
- Date published
- 02/10/2013
- Academic Unit
- Pharmacy; Epidemiology
- Record Identifier
- 9983995030502771
Metrics
18 Record Views